{"ATC Code":"G03XB01","Abbreviation":"","Aliases":["RU-486","Korlym","RU486","RU 486","Mifepristona","Mifepriston","RU 38486","RU-38486","Mifepristonum","CCRIS 9332"],"Biological Half-Life":"18 hours","CAS":"84371-65-3","ChEBI":"CHEBI:50692","ChEMBL":"CHEMBL438575","ChemicalClasses":["steroid"],"Chirality":"absolute","Color/Form":"Yellow powder","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Hormone Antagonists; Luteolytic Agents; Menstruation-Inducing Agents; Abortifacient Agents, Steroidal","Drug Indication":"For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.","Drug Warnings":"Confirmed or suspected ectopic pregnancy, undiagnosed adnexal mass, or IUD currently in place. Chronic adrenal failure or concurrent long-term corticosteroid therapy. Known hypersensitivity to mifepristone, misoprostol, or other prostaglandins. Hemorrhagic disorders, inherited porphyrias, or concurrent anticoagulant therapy.","DrugClasses":["hormone"],"DurationOfAction":"","EliminationHalfLife":"","European Community (EC) Number":"617-559-7","FDA Pharmacological Classification":"320T6RNW1F","HMDB ID":"HMDB0014972","HeavyAtomCount":32,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Hormone Antagonists; Luteolytic Agents; Menstruation-Inducing Agents; Abortifacient Agents, Steroidal","IUPACName":"(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one","InChI":"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1","InChIKey":"VKHAHZOOUSRJNA-GCNJZUOMSA-N","MeSH Pharmacological Classification":"Steroidal compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Steroidal.)","Melting Point":"191-196 °C","MolecularFormula":"C\u003csub\u003e29\u003c/sub\u003eH\u003csub\u003e35\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"429.6 g/mol","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.","Physical Description":"Solid","PrevSalts":[],"PubChemId":55245,"Record Description":["Mifepristone is a 3-oxo-Delta(4) steroid, an acetylenic compound and a tertiary amino compound. It has a role as a contraceptive drug, a synthetic oral contraceptive, a hormone antagonist and an abortifacient. It derives from a hydride of an estrane.","Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).","Mifepristone is a Progestin Antagonist. The mechanism of action of mifepristone is as a Progestational Hormone Receptor Antagonist.","Mifepristone, also known as RU-486, is a potent synthetic steroidal antiprogesterone which is used as a single dose in combination with misoprostol, a prostaglandin analogue, to induce medical abortion. Mifepristone with misoprostol have not been associated with serum enzyme elevations or with clinically apparent liver injury.","Mifepristone alone, without misoprostol, is also approved as therapy of Cushing syndrome where it is given in a higher dose and for extended periods. Long term higher doses of mifepristone have been linked to a low rate of serum enzyme elevations during therapy and rare instances of clinically apparent liver injury.","Mifepristone is a derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities.","MIFEPRISTONE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for cushing syndrome and has 35 investigational indications. This drug has a black box warning from the FDA.","A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome [PubChem]. The two marketed forms of mifepristone are Mifeprex\u0026#174; (mifepristone 200mg) and Korlym\u0026#8482; (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). ","A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.","Mifepristone is a 3-oxo-Delta(4) steroid, an acetylenic compound and a tertiary amino compound. It has a role as a contraceptive drug, a synthetic oral contraceptive, a hormone antagonist and an abortifacient. It derives from a hydride of an estrane.","LiverTox|Endocrine|Abortion|Antiprogestational"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Mifepristone","Name":"Mifepristone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q411240","Name":"Mifepristone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00834","Name":"Mifepristone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/55245","Name":"Mifepristone","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL438575","Name":"Mifepristone","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50692","Name":"Mifepristone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=84371-65-3","Name":"Mifepristone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014972","Name":"Mifepristone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00585","Name":"Mifepristone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/320T6RNW1F","Name":"Mifepristone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5023322","Name":"Mifepristone","Sub":false}]}],"SMILES":"CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O","Scheduling":[{"gov":"Australia","schedule":"S4 substance"},{"gov":"Canada","schedule":"prescription only substance"},{"gov":"United States","schedule":"prescription only substance"}],"Solubility":"7 [ug/mL] (The mean of the results at pH 7.4)","StoreUNII":["320T6RNW1F"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="118.828mm" version="1.2" viewBox="0 0 137.233 118.828" width="137.233mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#000000" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="119.0" stroke="none" width="138.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="136.195" x2="122.992" y1="42.517" y2="50.128"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="122.992" x2="109.788" y1="50.128" y2="57.74"/>
                        
                <line x1="124.209" x2="111.006" y1="52.241" y2="59.852"/>
                        
                <line x1="121.774" x2="108.57" y1="48.016" y2="55.627"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="96.41" x2="96.76" y1="65.048" y2="65.654"/>
                        
                <line x1="98.172" x2="98.771" y1="63.744" y2="64.784"/>
                        
                <line x1="99.933" x2="100.782" y1="62.44" y2="63.913"/>
                        
                <line x1="101.694" x2="102.793" y1="61.136" y2="63.042"/>
                        
                <line x1="103.455" x2="104.804" y1="59.832" y2="62.171"/>
                        
                <line x1="105.217" x2="106.815" y1="58.528" y2="61.301"/>
                        
                <line x1="106.978" x2="108.826" y1="57.224" y2="60.43"/>
                        
                <line x1="108.739" x2="110.837" y1="55.92" y2="59.559"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="96.585" x2="105.526" y1="65.351" y2="77.645"/>
                  
            <line class="bond" id="mol1bnd5" x1="105.526" x2="96.585" y1="77.645" y2="89.938"/>
                  
            <line class="bond" id="mol1bnd6" x1="96.585" x2="82.056" y1="89.938" y2="85.265"/>
                  
            <line class="bond" id="mol1bnd7" x1="82.056" x2="82.056" y1="85.265" y2="70.025"/>
                  
            <line class="bond" id="mol1bnd8" x1="96.585" x2="82.056" y1="65.351" y2="70.025"/>
                  
            <line class="bond" id="mol1bnd9" x1="82.056" x2="68.848" y1="70.025" y2="62.405"/>
                  
            <line class="bond" id="mol1bnd10" x1="68.848" x2="55.64" y1="62.405" y2="70.025"/>
                  
            <line class="bond" id="mol1bnd11" x1="55.64" x2="55.64" y1="70.025" y2="85.265"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="55.64" x2="42.432" y1="85.265" y2="92.885"/>
                        
                <line x1="55.64" x2="44.871" y1="88.08" y2="94.293"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="42.432" x2="29.224" y1="92.885" y2="85.265"/>
                  
            <line class="bond" id="mol1bnd14" x1="29.224" x2="16.016" y1="85.265" y2="92.885"/>
                  
            <line class="bond" id="mol1bnd15" x1="16.016" x2="16.016" y1="92.885" y2="108.125"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="17.236" x2="6.707" y1="108.828" y2="114.909"/>
                        
                <line x1="16.016" x2="5.487" y1="106.717" y2="112.798"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="114.909" y2="111.86850000000001"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="112.798" y2="109.7575"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="16.016" x2="29.224" y1="108.125" y2="115.745"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="29.224" x2="42.432" y1="115.745" y2="108.125"/>
                        
                <line x1="29.224" x2="39.994" y1="112.929" y2="106.716"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="42.432" x2="42.432" y1="92.885" y2="108.125"/>
                  
            <line class="bond" id="mol1bnd20" x1="42.432" x2="55.64" y1="108.125" y2="115.745"/>
                  
            <path class="bond" d="M55.657 116.087c-.127 .0 -.26 -.063 -.32 -.167c-.087 -.152 -.023 -.391 .128 -.479l13.208 -7.62c.048 -.048 .105 -.068 .163 -.068c.125 .0 .256 .093 .315 .197c.088 .151 .024 .39 -.128 .478l-13.208 7.62c-.047 .027 -.102 .039 -.158 .039z" id="mol1bnd21" stroke="none"/>
                  
            <line class="bond" id="mol1bnd22" x1="68.848" x2="68.848" y1="108.125" y2="92.885"/>
                  
            <line class="bond" id="mol1bnd23" x1="82.056" x2="68.848" y1="85.265" y2="92.885"/>
                  
            <line class="bond" id="mol1bnd24" x1="55.64" x2="68.848" y1="85.265" y2="92.885"/>
                  
            <path class="bond" d="M55.311 70.144l.658 -.239l-3.868 -16.192l-1.67 1.99l-2.558 -.452z" id="mol1bnd25" stroke="none"/>
                  
            <g class="bond" id="mol1bnd26">
                        
                <line x1="50.431" x2="60.228" y1="55.703" y2="44.029"/>
                        
                <line x1="49.468" x2="57.454" y1="53.056" y2="43.54"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd27" x1="60.228" x2="55.008" y1="44.029" y2="29.701"/>
                  
            <g class="bond" id="mol1bnd28">
                        
                <line x1="55.008" x2="39.993" y1="29.701" y2="27.048"/>
                        
                <line x1="53.199" x2="40.955" y1="31.857" y2="29.694"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd29" x1="39.993" x2="30.196" y1="27.048" y2="38.722"/>
                  
            <g class="bond" id="mol1bnd30">
                        
                <line x1="30.196" x2="35.415" y1="38.722" y2="53.049"/>
                        
                <line x1="32.969" x2="37.225" y1="39.21" y2="50.893"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd31" x1="50.431" x2="35.415" y1="55.703" y2="53.049"/>
                  
            <line class="bond" id="mol1bnd32" x1="39.993" x2="36.153" y1="27.048" y2="16.491"/>
                  
            <line class="bond" id="mol1bnd33" x1="31.464" x2="19.775" y1="12.14" y2="10.076"/>
                  
            <line class="bond" id="mol1bnd34" x1="37.624" x2="44.582" y1="9.341" y2="1.053"/>
                  
            <path class="bond" d="M81.708 69.988l.696 .074l3.354 -14.97l-2.089 -.222l-2.088 -.222z" id="mol1bnd35" stroke="none"/>
                  
            <path class="bond" d="M96.265 65.493l.64 -.284l-3.386 -10.839l-1.504 .666l-1.505 .667z" id="mol1bnd36" stroke="none"/>
                  
            <g class="bond" id="mol1bnd37">
                        
                <line x1="82.406" x2="81.706" y1="85.265" y2="85.265"/>
                        
                <line x1="82.656" x2="81.456" y1="87.442" y2="87.442"/>
                        
                <line x1="82.906" x2="81.206" y1="89.619" y2="89.619"/>
                        
                <line x1="83.156" x2="80.956" y1="91.796" y2="91.796"/>
                        
                <line x1="83.406" x2="80.706" y1="93.973" y2="93.973"/>
                        
                <line x1="83.656" x2="80.456" y1="96.15" y2="96.15"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd38">
                        
                <line x1="55.29" x2="55.99" y1="70.025" y2="70.025"/>
                        
                <line x1="55.04" x2="56.24" y1="67.847" y2="67.847"/>
                        
                <line x1="54.79" x2="56.49" y1="65.67" y2="65.67"/>
                        
                <line x1="54.54" x2="56.74" y1="63.493" y2="63.493"/>
                        
                <line x1="54.29" x2="56.99" y1="61.316" y2="61.316"/>
                        
                <line x1="54.04" x2="57.24" y1="59.139" y2="59.139"/>
                      
            </g>
                  
            <path class="bond" d="M69.198 92.885h-.7l-1.308 11.39h1.658h1.658z" id="mol1bnd39" stroke="none"/>
                  
            <path class="atom" d="M5.078 115.744q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 115.744q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm16" stroke="none"/>
                  
            <path class="atom" d="M36.724 15.175h-.72l-2.62 -4.066h-.029q.012 .238 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm28" stroke="none"/>
                  
            <g class="atom" id="mol1atm32">
                        
                <path d="M92.671 51.414q-.0 .757 -.256 1.328q-.256 .566 -.756 .881q-.501 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.751 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.233 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM88.807 51.414q.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.459q-.0 -.928 -.387 -1.452q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" stroke="none"/>
                        
                <path d="M87.59 53.867h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" fill="#FF0D0D" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M83.928 102.954h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" id="mol1atm33" stroke="none"/>
                  
            <path class="atom" d="M57.512 57.234h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" id="mol1atm34" stroke="none"/>
                  
            <path class="atom" d="M70.72 110.574h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" id="mol1atm35" stroke="none"/>
                
            <line class="hi" id="mol1bnd32" stroke="#3050F8" x1="36.153" x2="38.073" y1="16.491" y2="21.7695"/>
            <line class="hi" id="mol1bnd33" stroke="#3050F8" x1="31.464" x2="25.6195" y1="12.14" y2="11.108"/>
            <line class="hi" id="mol1bnd34" stroke="#3050F8" x1="37.624" x2="41.103" y1="9.341" y2="5.196999999999999"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Abortifacient Agents, Steroidal; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Hormone Antagonists; Luteolytic Agents; Menstruation-Inducing Agents","Title":"Mifepristone","UNII":"320T6RNW1F","Wikidata":"Q411240","Wikipedia":"Mifepristone","XLogP":3.8}